Briacell's Bria-IMT study receives no safety concerns

Dr. William Williams reports BRIACELL RECEIVES POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD (DSMB) FOR PHASE 3 STUDY IN METASTATIC BREAST CANCER The independent Data Safety Monitoring Board has issued its fourth consecutive positive recommendation following a review of safety data from Briacell Therapeutics Corp.'s pivotal phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in patients with metastatic breast cancer (NCT06072612). Following its review, the DSMB raised no safety concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol. Briacell's continuing pivotal phase 3 study is being conducted under fast-track designation granted by the U.S. Food and Drug Administration, reflecting the significant unmet medical need in metastatic breast cancer. "Repeated consecutive DSMB positive recommendations further strengthen our confidence in the excellent safety and tolerability profile of the Briacell regimen," commented Dr. William V. Williams, Briacell's president and chief executive officer. "We strongly believe in Bria-IMT's potential to transform cancer care and remain determined to make it a reality for patients with metastatic breast cancer who face urgent medical needs." About Briacell Therapeutics Corp. Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. We seek Safe Harbor.